SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

FDA Opens Comment Docket on VOQUEZNA Exclusivity Challenge

Phathom Pharmaceuticals said the FDA opened a public docket on legal and regulatory questions related to a challenge to VOQUEZNA’s NCE exclusivity through May 3, 2032.

PHAT

Related stories